Myriad’s Commitment to Fight Cancer
Transforming Patients’ Lives with Pioneering Genetic Tests
At Myriad, we are proud of our long-standing commitment to fighting cancer, which continues to exact a toll on society in the United States and across the world. In 2019 alone, it is estimated that more than 1.7 million new cases of cancer will be diagnosed in the United States and more than 600,000 people will die from the disease.
As the new president of Myriad Oncology, I am very excited to say that we are more committed than ever to providing pioneering personalized medicine tests to help physicians win the fight against cancer. For me, this commitment is deeply personal.
I started my career as a genetic counselor helping patients, and I was a customer of Myriad’s more than 20 years ago. I have seen how Myriad’s molecular diagnostic tests have transformed the lives of patients and their families. And closer to home, my own mother was diagnosed with breast cancer twice and my aunt is fighting metastatic breast cancer. I know they and many others like them are counting on us.
It has been 23 years since Myriad Genetics introduced the first-ever genetic test – called BRACAnalysis® – for hereditary breast and ovarian cancer. Since then, we have launched multiple other genetic tests for cancer including BRACAnalysis CDx, EndoPredict, myPath Melanoma, myRisk Hereditary Cancer, Prolaris and riskScore. These genetic tests are either the first of their kind or are best-in-class.
Over the years, we have pushed the boundaries of scientific innovation, advanced the field of personalized medicine and improved the health outcomes for people with cancer.
We continue to reinvest millions of dollars each year into R&D to ensure our products are answering patients’ most pressing questions about their disease: will I get cancer?, do I have cancer?, should I treat my cancer?, and how should I treat my cancer? Importantly, we are collaborating with leading academic institutions and scientists around the world as we design and invent future breakthroughs in personalized medicine.
Our researchers are conducting new studies in breast cancer, hereditary cancer, melanoma and prostate cancer. Our leading portfolio of companion diagnostic tests is helping many pharmaceutical companies develop new treatments faster and identify patients who can benefit from existing treatments such as PARP inhibitors.
Myriad also is responding to the needs of our customers. We are transforming our oncology business to take advantage of new digital technologies that will ensure healthcare professionals and patients have an easy and positive experience when ordering our tests. All the while, we are offering the highest quality and most accurate genetic tests available today.
We are proud of what we’ve accomplished and thank the thousands of oncologists for partnering with us as we work together in the fight against cancer. We stand committed to continuing the transformation in personalized medicine that we started more than two decades ago.
–Nicole Lambert, president, Myriad Oncology. #ASCO19